indinavir + efavirenz + adefovir dipivoxil + levocarnitine

This experimental combination antiretroviral therapy (cART) regimen was evaluated in the late 1990s and early 2000s for the treatment of HIV-1 infection, specifically targeting patients who had failed prior protease inhibitor-based therapy. The regimen consists of three active antiviral agents: **indinavir** (a protease inhibitor), **efavirenz** (a non-nucleoside reverse transcriptase inhibitor), and **adefovir dipivoxil** (a nucleotide reverse transcriptase inhibitor). **Levocarnitine** (L-carnitine) was included as a metabolic adjunct intended to mitigate mitochondrial toxicity and metabolic complications, such as lipodystrophy and hyperlactatemia, which are frequently associated with nucleoside/nucleotide analogs and protease inhibitors. The combination was primarily investigated by the AIDS Clinical Trials Group (ACTG) in the **ACTG 373** trial to assess safety, efficacy, and the protective effects of carnitine on mitochondrial function.

Brand names

Carnitor

Other names

Indinavir/Efavirenz/Adefovir/L-carnitineL-carnitine